Compare Plby Group Inc (PLBY) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Plby Group Inc vs BIO-TECHNE Corp — how do they compare? Plby Group Inc trades at $1 (market cap $122.20M), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 93× Plby Group Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Plby Group Inc for 24 Days and BIO-TECHNE Corp for 63 Days on average.
| PLBY | TECH | |
|---|---|---|
Market Cap | $122.20M | $11.37B |
Volume | 228,361 | 3,153,511 |
Sector | Consumer Cyclical | Health |
52-Week High | $2.71 | $72.61 |
52-Week Low | $0.99 | $43.31 |
Typical Hold Time | 24 Days | 63 Days |
Enterprise Value | $267.79M | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PLBY Group trades at $0.99, down 5.12% today, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue stabilizing around $120M and narrowing losses from -$278M in 2022 to -$13M in 2025. Positive operating cash flow of $18K in 2025 marks a turnaround from previous negative figures. Recent leadership appointments signal strategic focus on brand growth.
While analyst consensus remains bullish (75% buy ratings), high debt levels and negative shareholder equity pose significant risks. The path to sustained profitability depends on successful execution of licensing and media strategies. Near-term catalysts include Q3 2026 earnings where the company faces a $0.01 EPS expectation.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
